Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

9342-8530 Quebec Inc DGCRF

Healthcare Biotechnology
Diagnocure Inc is a Canada based biotechnology company. It is primarily engaged in the business activity of development and commercialization of products relating to the diagnosis of cancer. The group generates its revenue from research and license agreement. The head office of the company is located in Quebec, Canada.


GREY:DGCRF - Post by User

9342-8530 Quebec Inc
Bullboard Posts
User Avatar Image
(34)
•••
Comment by SurfForWealthon Mar 09, 2004 10:11pm
112 Views
Post# 7184949

RE: 3 M for ImmunoCyt in 2004-2005

RE: 3 M for ImmunoCyt in 2004-2005I cannot read french but is this saying that the revenue estimate for this bladder test product will increase from $1M to $3M? Is that for FY2005 (Oct 31)? or can some of that increase be incurred in FY2004? The guidance for FY2004 for this product was originally for $1M in November. Also I just watched the Robtv interview from Nov 26, 2003 again, which is still available on the CUR website. The CEO clearly specified that the Gen-Probe Gen 2 test was expected in 2-2 1/2 years from November 2003. The date given last week of 1-1 1/2 years from now is much ahead of this estimated schedule, by at least 8 months. Cheers!!!
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities